Sera Prognostics (Nasdaq: SERA) highlights its PreTRM® Test, a blood-based proteomic test taken between weeks 18–21 of pregnancy to predict individualized risk of spontaneous preterm birth in asymptomatic singleton pregnancies. The test measures the ratio of IBP4 to SHBG to identify women at higher risk so physicians can plan tailored care.According to Sera, the PRIME randomized controlled trial of ~5,000 participants showed that PreTRM-guided care using vaginal progesterone, low-dose aspirin, and frequent nurse check-ins reduced births before 32 weeks by more than 50%, births before 35 weeks by more than 30%, and NICU admissions by 20%. Sera estimates that full national adoption could reduce U.S. NICU admissions by about 94,300 annually. The company notes growing access through insurance, financial assistance, interest-free payment plans, and Illinois Medicaid coverage for proteomic prenatal testing, including PreTRM, effective July 1, 2026.

Dr. Thaïs Aliabadi, a board-certified OB-GYN and co-host of the SHE MD podcast, makes the case that preterm birth risk is personal, knowable between weeks 18 and 21 of pregnancy, and worth a direct conversation with your doctor. She points to a simple blood test, the PreTRM® Test from...

Analyst Bill Bonello highlighted recently published clinical trial results showing the ability of the company's PreTRM test to reduce preterm births and NICU admissions.

Coupling biomarker-guided screening with a targeted treatment bundle reduced newborn mortality, hospital stays, and other complications over standard care, according to a recent study.

Jefferies analyst Tycho Peterson cited the large addressable market for the company's PreTRM blood test for assessing pregnant women's risk of preterm birth.

The firm has been engaging with payors and insurance plan administrators following the release of results from its study on the use of the firm's PreTRM Test.

Highlights from the fourth day included preliminary data from Sera Prognostics for its PreTRM blood test.

Jefferies starts coverage of Sera Prognostics with a Buy rating, highlighting its PreTRM test for predicting preterm birth and $1.6B U.S. market potential.

Reported Thursday, Jul 9 - 4:10pm EDT (TheFly subscription required to read more.)

A recent study reveals that using the PreTRM Test can lead to a 22% drop in NICU admissions among first-time pregnant mothers. This finding highlights the importance of innovative prenatal care.

Sera Prognostics, Inc. reports its first-quarter 2026 results, showcasing advancements in maternal health and financial insights. Key developments include published clinical studies and strategic updates.

A new study reveals that the PreTRM Test successfully decreases preterm births and enhances neonatal outcomes by using personalized screening.

Sera Prognostics shares positive financial results for Q1 2025, enhancing focus on maternal health and exploring new market opportunities for its PreTRM Test.

Sera Prognostics, known for its innovative medical solutions, has announced a public offering totaling $50 million to advance maternal health initiatives.

In 1,783 nulliparous participants, PreTRM-guided care reduced severe composite morbidity to 6.4% from 9.1% and needed 28 screenings per NICU case prevented.

Dr. Tiffany Inglis joins Sera Prognostics from Elevance Health to lead clinical operations. Former OBGYN to advance PreTRM Test adoption and drive Medicaid coverage as company prepares for PRIME study publication.

Sera Prognostics (NASDAQ: SERA) reported its Q1 2025 financial results, showing revenue of $38,000 compared to zero in Q1 2024. The company posted a net loss of $8.2 million, slightly higher than the $8.1 million loss in the prior year. Total operating expenses increased to $9.3 million from $9.1 million year-over-year.Following successful PRIME study results, Sera is increasing engagement with payors and pursuing Medicaid opportunities across three states for PreTRM test implementation pilots. The company maintains a strong financial position with $114.2 million in cash and equivalents. R&D expenses decreased 9% to $3.3 million, while SG&A expenses rose to $5.9 million from $5.4 million as the company invests in strategic growth initiatives.

Sera Prognostics secures $50M through stock & warrant offering at $4.00/share to expand PreTRM test presence, pursue FDA approval, and enter EU markets.

Sera Prognostics announces stock offering to accelerate US commercial growth, EU market entry, and advance PreTRM test adoption and FDA approval process.

Published in the journal PREGNANCY, the PRIME Study demonstrates significant improvements in neonatal outcomes with early risk screening and targeted interventions. SALT LAKE CITY, Jan. 7, 2026 /PRNewswire/ -- A randomized controlled trial of 5,018 women has found that a simple blood...

Screen-guided care using the PreTRM blood test reduced preterm birth–related complications and NICU use.